Predictive factors of romiplostim response in patients with refractory aplastic anemia: data from two clinical trials

  • Jang, Jun Ho; 
  • Mitani, Kinuko; 
  • Tomiyama, Yoshiaki; 
  • Miyazaki, Koji; 
  • Nagafuji, Koji; 
  • 외 18명
Citations

WEB OF SCIENCE

4
Citations

SCOPUS

4

초록

The thrombopoietin receptor agonist (TPO-RA) romiplostim has been shown to be efficacious in the treatment of aplastic anemia (AA) refractory to immunosuppressive therapy. However, there are few reports on predictors of TPO-RA efficacy. We analyzed patient clinical and baseline laboratory data from two clinical trials that enrolled patients with refractory AA, a phase 2 dose-finding study (NCT02094417) and a phase 2/3 study (NCT02773290), to determine predictors of romiplostim efficacy. Data from 66 patients (35 from the phase 2 dose-finding study and 31 from the phase 2/3 study), median age 47.0 (range 20-78) years, were analyzed. Of these, 51.5% (34/66) had non-severe AA, 86.4% (57/66) had received prior therapy with anti-thymocyte globulin plus cyclosporine, and 80.3% (53/66) were transfusion-dependent. At 27 weeks, no patients achieved a complete response, 57.4% (35/61) achieved a partial response, 49.0% (24/49) became red blood cell transfusion-independent, and 56.8% (21/37) became platelet transfusion-independent. Univariate logistic regression analysis identified duration from diagnosis (P = 0.040), baseline reticulocyte count (P < 0.001), and platelet count (P < 0.001) as predictors of response to romiplostim at 27 weeks. Receiver operating characteristic curve analysis identified a cutoff value of 30.77 x 10(9)/L at baseline as the threshold reticulocyte count to predict response to romiplostim in patients with refractory AA (sensitivity: 82.9%, specificity: 73.1%). Of note, the initial dose included in this analysis was lower than that used in real-world clinical practice, as data from the phase 2 dose-finding study were used. This study identified factors predicting response to romiplostim at 27 weeks.

키워드

Aplastic anemia; Refractory; Romiplostim; Hematological response; Predictor; Reticulocyte; DIAGNOSIS
제목
Predictive factors of romiplostim response in patients with refractory aplastic anemia: data from two clinical trials
저자
Jang, Jun Ho; Mitani, Kinuko; Tomiyama, Yoshiaki; Miyazaki, Koji; Nagafuji, Koji; Usuki, Kensuke; Uoshima, Nobuhiko; Fujisaki, Tomoaki; Kosugi, Hiroshi; Matsumura, Itaru; Sasaki, Ko; Kizaki, Masahiro; Sawa, Masashi; Hidaka, Michihiro; Kobayashi, Naoki; Ichikawa, Satoshi; Yonemura, Yuji; Murotani, Kenta; Shimizu, Mami; Matsuda, Akira; Ozawa, Keiya; Nakao, Shinji; Lee, Jong Wook
DOI
10.1007/s00277-025-06337-7
발행일
2025-07
유형
Article; Early Access
저널명
Annals of Hematology
권
104
호
8
페이지
4003 ~ 4011